cicletanine has been researched along with endothelin-1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagrov, AY; Dmitrieva, RI; Droy-Lefaix, MT | 1 |
| Bagrov, AY; Dmitrieva, RI; Dorofeeva, NA; Droy-Lefaix, MT; Fedorova, OV; Lakatta, EG; Lopatin, DA | 1 |
2 other study(ies) available for cicletanine and endothelin-1
| Article | Year |
|---|---|
Vasorelaxant effects of cicletanine and its (+)- and (-)-enantiomers in isolated human pulmonary arteries.
Topics: Adult; Antihypertensive Agents; Atrial Natriuretic Factor; Dose-Response Relationship, Drug; Drug Synergism; Endothelin-1; Humans; In Vitro Techniques; Male; Middle Aged; Nitroprusside; Pulmonary Artery; Pyridines; Stereoisomerism; Vasodilator Agents | 1998 |
Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism.
Topics: Animals; Antihypertensive Agents; Brain; Bufanolides; Cyclic GMP; Endothelin-1; Enzyme Inhibitors; Humans; In Vitro Techniques; Male; Mesenteric Arteries; Middle Aged; Protein Kinase C; Pyridines; Rats; Sodium-Potassium-Exchanging ATPase; Vasoconstriction | 2000 |